Last week ended with an interactive cost-effectiveness workshop ✍ Today, we start the last week of the @HarvardChanSPHSummerSummer Course RDS286 'Decision Analysis in Clinical Research'. 💪 #DecisionAnalysis #Costeffectiveness #Workshop #RDS286

Meta-analysis of 24 randomized controlled trials demonstrates an increased risk of CV events amongst patients with advanced and metastatic prostate cancer commencing androgen receptor signaling inhibitors. ja.ma/3LBSGYJ

🌟 Exciting day at the @HarvardChanSPHSummer Summer Course RDS286 'Decision Analysis in Clinical Research'! 🌟 Today, @EveWittenbergintroduced us to some fascinating concepts, including: 🔹 𝗣𝘀𝘆𝗰𝗵𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗣𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀 𝗶𝗻 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗮𝗸𝗶𝗻𝗴:

Excellent example of combination of clinical and molecular data to predict activity of targeted single agent in HR+ MBC. International Society of Liquid Biopsy WCM Englander Institute for Precision Medicine #MBC

#ESMO24: ESMO has announced the recipients of the 2024 ESMO Society Awards in recognition of their work in strengthening the oncology field and supporting fellow oncologists in their professional careers. 📌ow.ly/Kopk50SRQUk

🔥🔥

🔥“A comprehensive, integrated, unifying approach that aims to sustainably balance and optimise the health of people and ecosystems must become a top priority worldwide” Unmissable editorial by Dario Trapani

🔥🔥🔥What a wonderful final foy our Program in Clinical Effectiveness!!!! Harvard T.H. Chan School of Public Health Harvard University

Congratulations, Christine Brunner and the Med. Uni. Innsbruck breast centre team led by Christian Marth, to a great publication in JCO, not only giving an important heads-up on ONJ but demonstrating outstanding population based OS results in mBC! ABCSG ascopubs.org/doi/10.1200/JC…

Patients with post–COVID-19 mRNA vaccination myocarditis, contrary to patients with post–COVID-19 myocarditis, have a lower frequency of cardiovascular complications than those with conventional myocarditis at 18 months. ja.ma/3yJo98F #ESCCongress

Today I saw a BC survivor who moved to Boston. She can’t find a PCP for 8 months after calling > 6 places. I ordered mammo, DEXA, labs, colonoscopy for + cologuard. I refilled thyroid meds, BP meds which were out and causing symptoms. This is 🇺🇸

📢 Just out on ESMO Open our last contribution on the role of gBRCA-PV in post-PARPi myeloid neoplasms, in pts with ovarian cancer 🚨 In heavily pretreated patients, gBRCA impact seems to be even higher than PARPi exposure Thanks to all the coauthors! sciencedirect.com/science/articl…

🔥 Happy to share our last contribution regarding ESR1m, endocrine-responsive mBC 🧐 Patient selection according to clinical and molecular features is the key in the post-CDK4/6i setting Thanks to all the coauthors! sciencedirect.com/science/articl… ESMO Open

New paper from Brittany Bychkovsky, MD and colleagues on the incidence of endometrial cancer in #BRCA mutation carriers. Open access here⬇️ pubmed.ncbi.nlm.nih.gov/39173195/ Nadine Tung MD Amber Aeilts Beth Karlan Robert Fruscio Charis Eng, MD, PhD Olufunmilayo Olopade Fergus Couch Teresa Alonso Gordoa Steven Narod

I totally agree with this issue 🛑 Stop using diseases as attributive adjectives of patients

Can't express more gratitude to ESMO - Eur. Oncology for conferring the #ESMO24 Award to Ann Partridge MD, MPH for her infinite #Commitment & #Passion addressing the challenges of every patients with #cancer , framed in a research that person-oriented, and of tangible impact! #ESMOAmbassador

🧐Treatment algorithm of mTNBC in 2024 Stellar presentation by G Curigliano MD PhD ESMO - Eur. Oncology IEO Università degli Studi di Milano #ESMO2024

These curves represent the true goal of our job and the treatment we would like to prescribe every day to our patients

At central testing, 339/528 (64%) of pts with HER2 0 have membrane staining ("ultralow") 226/349 (65%) pts with HER2 0 at local testing have membrane staining (> or = "ultralow") 🧐2/3 of pts with HR+/HER2 0 mBC may have access to T-DXd

New Mozart dropping soon.